What You Should Know:
– SetPoint Medical, a company focused on developing innovative therapies for chronic autoimmune diseases secures $140M in private financing. This includes the final $25M tranche of its Series C funding and a substantial $115M Series D round co-led by Elevage Medical Technologies and Ally Bridge Group.
– The funding will fuel the commercialization of the SetPoint System, a groundbreaking neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis (RA), and advance the company’s pipeline for other autoimmune conditions.
Neuroimmune Modulation for Autoimmune Disease
The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation. This innovative therapy aims to modulate the body’s inflammatory response through targeted electrical stimulation of the vagus nerve. The successful commercialization of this technology could offer a significant new treatment option for individuals living with moderate-to-severe RA and holds promise for addressing other chronic autoimmune conditions in the future. The significant funding secured by SetPoint Medical underscores the potential of this novel therapeutic approach and its potential to transform the lives of millions affected by autoimmune diseases.
Preparing for Commercial Market Launch
SetPoint Medical is actively preparing for the commercial launch of its SetPoint System. To this end, the company has announced two key executive appointments. Erik Styacich, former Vice President of Sales at Valencia Technologies, has joined SetPoint as Vice President of Sales. Spencer Bailey, who brings extensive experience in market access and reimbursement from previous leadership roles at neuromodulation companies like MicroTransponder, Inc., has been appointed as Vice President of Market Access & Reimbursement.
“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026,” added Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”
